← Home / Altimmune, Inc. (ALT)
Stock Analysis
Altimmune, Inc. (ALT)
ALT
ALT · Market data
2.84 -4.70%
Track ALT in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ALT price is:
52W Range Position
7%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 14:42 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
2.89
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
16
●
Material Agreement
MEDIUM
ALT material agreement
(the “Company”) announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year.
8-K Filing • SEC EDGAR
MAY
13
●
Financial Results
HIGH
Altimmune Announces First Quarter 2026 Financial Results and Business Update
(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.
8-K Filing • SEC EDGAR
What's Driving ALT?
📈 Technical recovery is improving
Momentum is Neutral. Watch 2.89 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
46.0
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 2.58 and resistance at 2.95. The chart still needs to reclaim resistance to improve meaningfully, while any loss of support would keep weakness in control.
Price Chart
ALT — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$369.8M
Company size
EV
$307.8M
Debt-adjusted value
P/E
-4.1
Not meaningful
P/B
1.3
Low book multiple
EV/EBIT
-3.2
Not meaningful
P/FCF
-5.2
Not meaningful
FCF Yield
-19.37%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
5,000
↗ Strong
📈 Net Income
-22.56M
↘ Negative
🧮 EPS (Basic)
-0.18
↘ Negative
Altimmune, Inc.
Related Opportunities